ArticleMedComm2023

A multicenter single-arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer.

Qiyun Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.